Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF relating to DBV Technologies shares (the “Liquidity Contract”).

The Liquidity Contract is implemented in accordance with AMF Decision No. 2021-01 of June 22, 2021 on liquidity contracts on equity securities accepted as a market practice.

When the Liquidity Contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account: 41,159 DBV Technologies shares, € 432,367.25. It is reminded that, as of December 31, 2025, the following assets appeared on the liquidity account: 74,580 DBV Technologies shares, € 527,891.63. As of June 30, 2026, the following assets appeared on the liquidity account: 146,321 DBV Technologies shares, € 396,088.22.

Over the period from January 1, 2026 to June 30, 2026, the following transactions were executed: 1,989 buy transactions, 2,012 sales transactions. Over this same period, the volumes traded represented: 2,707,915 shares and € 8,836,273.65 on purchases, 2,636,174 shares and € 8,704,457.81 on sales.

Details of the transactions executed under the Liquidity Contract are provided in the appendix to this press release.

About DBV Technologies DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN ® patch tech...